Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,852
datasets available to search
ShareScore release 0.7.1
Dataset results
2,852 results for “Hepatocellular carcinoma”
Protein expression of hepatocellular carcinoma in a fibrotic liver in mice
<p>Hepatocellular carcinoma (HCC) is a liver tumor that arises in patients with cirrhosis. One of the key players in the progression of cirrhosis to HCC is the hepatic stellate cell, which is activated during liver damage. Activated stellate cells play an essential role in the pathogenesis of HCC by creating a fibrotic micro-environment that sustains tumor growth and by producing growth factors and cytokines that enhance tumor cell proliferation and migration. We assessed the role of endoplasmic reticulum (ER) stress in the cross-talk between hepatic stellate cells and HCC-cells. Mice with a fibrotic HCC were treated with the IRE1A-inhibitor 4mu8C. The oncogenic protein expression was assessed using a multiplex proximity extension assay for ninety-two biomarkers in the murine exploratory panel (Olink Bioscience, Uppsala, Sweden) in liver samples from healthy mice, mice with HCC and mice with HCC treated with the IRE1A-inhibitor 4mu8C.</p>
Data from: Identification of biomarkers for Barcelona Clinic Liver Cancer staging and overall survival of patients with hepatocellular carcinoma
The aim of the current study was to identify biomarkers that correlate with the Barcelona Clinic Liver Cancer (BCLC) staging system and prognosis of patients with hepatocellular carcinoma (HCC). We downloaded 4 gene expression datasets from the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo), and screened for genes that were differentially expressed between HCC and normal liver tissues, using significance analysis of the microarray algorithm. We used a weighted gene co-expression network analysis (WGCNA) to identify hub genes that correlate with BCLC staging, functional enrichment analysis to associate hub genes with their functions, protein-protein interaction network analysis to identify interactions among hub genes, UALCAN analysis to assess gene expression levels based on tumour stage, and survival analyses to clarify the effects of hub genes on patients' overall survival (OS). We identified 50 relevant hub genes using WGCNA; among them, 13 genes (including TIGD5, C8ORF33, NUDCD1, INSB8, and STIP1) correlated with OS and BCLC staging. Significantly enriched gene ontology biological process terms included RNA processing, non-coding RNA processing and phosphodiester bond hydrolysis, and 6 genes were found to interact with 10 or more hub genes. We identified several candidate biomarkers that correlate with BCLC staging and OS of HCC. These genes might be used for prognostic assessment and selection of HCC patients for surgery, especially those with intermediate or advanced disease.
Data from: CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma
CXC ligand 17 (CXCL17) is a novel CXC chemokine whose clinical significance remains largely unknown. In the present study, we characterized the prognostic value of CXCL17 in patients with hepatocellular carcinoma (HCC) and evaluated the association of CXCL17 with immune infiltration. We examined CXCL17 expression in 227 HCC tissue specimens by immunohistochemical staining, and correlated CXCL17 expression patterns with clinicopathological features, prognosis, and immune infiltrate density (CD4 T cells, CD8 T cells, B cells, natural killer cells, neutrophils, macrophages). Kaplan-Meier survival analysis showed that both increased intratumoral CXCL17 (P = 0.015 for overall survival [OS], P = 0.003 for recurrence-free survival [RFS]) and peritumoral CXCL17 (P = 0.002 for OS, P<0.001 for RFS) were associated with shorter OS and RFS. Patients in the CXCL17low group had significantly lower 5-year recurrence rate compared with patients in the CXCL17high group (peritumoral: 53.1% vs. 77.7%, P<0.001, intratumoral: 58.6% vs. 73.0%, P = 0.001, respectively). Multivariate Cox proportional hazards analysis identified peritumoral CXCL17 as an independent prognostic factor for both OS (hazard ratio [HR] = 2.066, 95% confidence interval [CI] = 1.296–3.292, P = 0.002) and RFS (HR = 1.844, 95% CI = 1.218–2.793, P = 0.004). Moreover, CXCL17 expression was associated with more CD68 and less CD4 cell infiltration (both P<0.05). The combination of CXCL17 density and immune infiltration could be used to further classify patients into subsets with different prognosis for RFS. Our results provide the first evidence that tumor-infiltrating CXCL17+ cell density is an independent prognostic factor that predicts both OS and RFS in HCC. CXCL17 production correlated with adverse immune infiltration and might be an important target for anti-HCC therapies.
Senegenin Modulates O-GlcNAc Glycosylation to Thwart Hepatocellular Carcinoma Progression
Open the record for dataset details and reuse information.
Systematic analysis identifies CDKN2A as a prognostic biomarker for hepatocellular carcinoma
Open the record for dataset details and reuse information.
data - ERα Inhibits the Progression of Hepatocellular Carcinoma by Regulating the CircRNA/miRNA/SMADs Network
Open the record for dataset details and reuse information.
Downregulation of ST6GAL1 promotes liver inflammation and predicts adverse prognosis in hepatocellular carcinoma
<p>Original file of <em>Downregulation of ST6GAL1 promotes liver inflammation and predicts adverse prognosis in hepatocellular carcinoma.</em></p>
Network Pharmacology-based Approach combined with Bioinformatic Analytics to Elucidate the Potential of Curcumol Against Hepatocellular Carcinoma
<p>File S1: Expression distribution of common targets; File S2: GSEA result of common targets, File S3: Rare data for top 10 most enriched GO terms in biological process, cellular component, and molecular function of common targets, File S4: Rare data for KEGG enrichment result of common targets, File S5: Rare data for cluster classification performed by MCODE, File S6: Rare data for GO terms and KEGG pathways enrichment analyses of cluster 1 and cluster 2, File S7: Prognosis-related genes, Table S1: Putative targets of curcumol.</p>
Downregulation of ST6GAL1 promotes liver inflammation and predicts adverse prognosis in hepatocellular carcinoma
<p>Original file of <em>Downregulation of ST6GAL1 promotes liver inflammation and predicts adverse prognosis in hepatocellular carcinoma.</em></p>
Comparative Analysis of Gut Microbiota in Hepatocellular Carcinoma and Hepatitis
<p><span><span> </span></span><span>The differential abundance of flora was modeled using support vector machine (SVM) methodology. Predictive performance for hepatocellular carcinoma and hepatitis was assessed using the model. 3 genera including <em>Paraprevotella</em>, <em>Pasteurellaceae</em>, and <em>Prevotellaceae</em> showed superior predictive performance for HCC, whereas <em>Oscillibacter</em>, <em>Clostridium_XVIII</em>, while 5 genera including <em><span> </span>Eggerthella</em> exhibited better predictive ability for HBV.</span></p> <p><span> </span></p>
New incidence or recurrence hepatocellular carcinoma (HCC) in genotype 4 hepatitis C virus treated with sofosbuvir/daclatasvir with or without ribavirin
<p><span><b>Background</b>: Several studies have resulted in controversial data about the recurrence or new incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C who were treated with direct-acting antivirals (DAAs). </span></p> <p><span><b>Aim:</b> This observational study aimed to assess the occurrence rate of HCC in patients who developed a sustained virological response (SVR).. </span></p> <p><span><b>Methods</b>: A six-month prospective study was done at the National Hepatology and Tropical Medicine Research Institute [NHTMRI] in Cairo, Egypt on 150 chronic hepatitis C (CHC) patients treated with sofosbuvir and daclatasvir with or without ribavirin. Patients were assigned into two groups according to their laboratory values to either receive sofosbuvir/daclatasvir and ribavirin (S/D/R) or receive only sofosbuvir/daclatasvir (S/D). The main outcome measure was the occurrence of HCC.</span></p> <p><span><b>Results</b>: SVR-12 was 100%. 8.5% of patients developed HCC in the S/D/R group, while 0% in the S/D group.</span></p> <p><span><b>Conclusion:</b> New incidence or recurrence of HCC may occur in CHC genotype 4 cirrhotic patients receiving sofosbuvir/daclatasvir and ribavirin (difficult to treat) although achieving SVR. The cause of HCC development in this study is cirrhosis, not the administered DAAs.</span></p>
Silencing of TRAF5 enhances necroptosis in hepatocellular carcinoma by inhibiting LTBR-mediated NF-κB signaling
<p>Raw data of the article titled Silencing of TRAF5 enhances necroptosis in hepatocellular carcinoma by inhibiting LTBR-mediated NF-κB signaling</p>
Gut microbiota as mediator and moderator between hepatitis B virus and hepatocellular carcinoma
<p>A STORMS (Strengthening The Organizing and Reporting of Microbiome Studies) checklist is available here.</p>
TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
ClinicalTrials.gov study NCT00618384. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife
ClinicalTrials.gov study NCT02363218. IPD Sharing: Not stated. Countries: 1. Publications: 16.
Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging
ClinicalTrials.gov study NCT01387503. IPD Sharing: Not stated. Countries: 1. Publications: 5.
Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma
ClinicalTrials.gov study NCT02243384. IPD Sharing: Not stated. Countries: 1. Publications: 24.
Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma
ClinicalTrials.gov study NCT05573282. IPD Sharing: NO. Countries: 1. Publications: 3.
Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma
ClinicalTrials.gov study NCT00768157. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Dietary Intervention and Gut Microbiota in Hepatocellular Carcinoma (HCC)
ClinicalTrials.gov study NCT07143955. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.